Does the media refer more to ARTV or XLO?

In the previous week, Artiva Biotherapeutics had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 4 mentions for Artiva Biotherapeutics and 2 mentions for Xilio Therapeutics. Artiva Biotherapeutics' average media sentiment score of 0.97 beat Xilio Therapeutics' score of 0.94 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer XLO or JMAC?

Xilio Therapeutics currently has a consensus target price of $28.00, suggesting a potential upside of 243.56%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Xilio Therapeutics is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, XLO or JMAC?

Maxpro Capital Acquisition has lower revenue, but higher earnings than Xilio Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xilio Therapeutics $43.77M 1.23 -$35.04M -$3.55 N/A Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Does the media prefer XLO or JMAC?

In the previous week, Xilio Therapeutics had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Maxpro Capital Acquisition. Xilio Therapeutics' average media sentiment score of 0.94 beat Maxpro Capital Acquisition's score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maxpro Capital Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IFRX or XLO more profitable?

InflaRx has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. InflaRx's return on equity of -88.30% beat Xilio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -88.30% -65.77% Xilio Therapeutics -58.52% -151.42% -27.61%

Do analysts rate XLO or TLSA?

Xilio Therapeutics presently has a consensus target price of $28.00, indicating a potential upside of 243.56%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Xilio Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, XLO or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Xilio Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xilio Therapeutics $43.77M 1.23 -$35.04M -$3.55 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Does the media prefer XLO or TLSA?

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 2 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.94 beat Tiziana Life Sciences' score of 0.63 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xilio Therapeutics (XLO) Competitors

$8.15 -0.05 (-0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$8.14 -0.01 (-0.06%)

As of 06:42 PM Eastern

Compare

XLO vs. IMDX, ARTV, JMAC, IFRX, and TLSA

Should you buy Xilio Therapeutics stock or one of its competitors? MarketBeat compares Xilio Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xilio Therapeutics include Oncocyte (IMDX), Artiva Biotherapeutics (ARTV), Maxpro Capital Acquisition (JMAC), InflaRx (IFRX), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry.

How does Xilio Therapeutics compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Oncocyte presently has a consensus price target of $12.00, indicating a potential upside of 99.00%. Xilio Therapeutics has a consensus price target of $28.00, indicating a potential upside of 243.56%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Xilio Therapeutics is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Oncocyte has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

In the previous week, Xilio Therapeutics had 1 more articles in the media than Oncocyte. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Oncocyte. Xilio Therapeutics' average media sentiment score of 0.94 beat Oncocyte's score of 0.44 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncocyte	Neutral
Xilio Therapeutics	Positive

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 2.1% of Oncocyte shares are owned by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Xilio Therapeutics has higher revenue and earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	48.08	-$50.22M	-$1.48	N/A
Xilio Therapeutics	$43.77M	1.23	-$35.04M	-$3.55	N/A

Xilio Therapeutics has a net margin of -58.52% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Summary

Xilio Therapeutics beats Oncocyte on 11 of the 17 factors compared between the two stocks.

How does Xilio Therapeutics compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Artiva Biotherapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Artiva Biotherapeutics' return on equity of -73.15% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Artiva Biotherapeutics has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Xilio Therapeutics has higher revenue and earnings than Artiva Biotherapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	688.60	-$83.86M	-$3.54	N/A
Xilio Therapeutics	$43.77M	1.23	-$35.04M	-$3.55	N/A

Artiva Biotherapeutics presently has a consensus price target of $39.00, indicating a potential upside of 460.02%. Xilio Therapeutics has a consensus price target of $28.00, indicating a potential upside of 243.56%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Artiva Biotherapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

54.3% of Xilio Therapeutics shares are held by institutional investors. 21.4% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Artiva Biotherapeutics had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 4 mentions for Artiva Biotherapeutics and 2 mentions for Xilio Therapeutics. Artiva Biotherapeutics' average media sentiment score of 0.97 beat Xilio Therapeutics' score of 0.94 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Artiva Biotherapeutics beats Xilio Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Xilio Therapeutics compare to Maxpro Capital Acquisition?

Xilio Therapeutics (NASDAQ:XLO) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Maxpro Capital Acquisition has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Maxpro Capital Acquisition's return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Maxpro Capital Acquisition	N/A	N/A	N/A

Xilio Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

Xilio Therapeutics currently has a consensus target price of $28.00, suggesting a potential upside of 243.56%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Xilio Therapeutics is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Maxpro Capital Acquisition has lower revenue, but higher earnings than Xilio Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.23	-$35.04M	-$3.55	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Xilio Therapeutics had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Maxpro Capital Acquisition. Xilio Therapeutics' average media sentiment score of 0.94 beat Maxpro Capital Acquisition's score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maxpro Capital Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Xilio Therapeutics and Maxpro Capital Acquisition tied by winning 6 of the 12 factors compared between the two stocks.

How does Xilio Therapeutics compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

42.4% of InflaRx shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Xilio Therapeutics had 1 more articles in the media than InflaRx. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for InflaRx. Xilio Therapeutics' average media sentiment score of 0.94 beat InflaRx's score of 0.75 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
InflaRx	Positive
Xilio Therapeutics	Positive

InflaRx has a beta of 2.42, indicating that its share price is 142% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

InflaRx has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. InflaRx's return on equity of -88.30% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

InflaRx currently has a consensus target price of $7.00, indicating a potential upside of 239.81%. Xilio Therapeutics has a consensus target price of $28.00, indicating a potential upside of 243.56%. Given Xilio Therapeutics' higher possible upside, analysts plainly believe Xilio Therapeutics is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Xilio Therapeutics has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	4,963.91	-$51.63M	-$0.71	N/A
Xilio Therapeutics	$43.77M	1.23	-$35.04M	-$3.55	N/A

Summary

InflaRx and Xilio Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Xilio Therapeutics compare to Tiziana Life Sciences?

Xilio Therapeutics (NASDAQ:XLO) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Tiziana Life Sciences has lower revenue, but higher earnings than Xilio Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.23	-$35.04M	-$3.55	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Tiziana Life Sciences has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Tiziana Life Sciences' return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Tiziana Life Sciences	N/A	N/A	N/A

Xilio Therapeutics presently has a consensus target price of $28.00, indicating a potential upside of 243.56%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Xilio Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Xilio Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

54.3% of Xilio Therapeutics shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 2 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.94 beat Tiziana Life Sciences' score of 0.63 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tiziana Life Sciences beats Xilio Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Xilio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XLO vs. The Competition

Export

Metric	Xilio Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$53.92M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-2.29	17.78	22.39	24.18
Price / Sales	1.23	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	1.11	6.63	9.84	6.72
Net Income	-$35.04M	$24.20M	$3.57B	$337.19M
7 Day Performance	-2.28%	-3.24%	-1.16%	0.48%
1 Month Performance	-2.04%	0.53%	3.85%	5.07%
1 Year Performance	-13.87%	47.24%	27.40%	34.25%

Xilio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XLO Xilio Therapeutics	2.7344 of 5 stars	$8.15 -0.6%	$28.00 +243.6%	-16.3%	$53.92M	$43.77M	N/A	70	News Coverage
IMDX Oncocyte	2.6417 of 5 stars	$6.44 +5.7%	$12.00 +86.3%	N/A	$196.65M	$4.05M	N/A	120	Short Interest Increase Gap Down
ARTV Artiva Biotherapeutics	4.2315 of 5 stars	$7.67 -2.5%	$39.00 +408.5%	+254.1%	$194.52M	N/A	N/A	81	Short Interest Increase
JMAC Maxpro Capital Acquisition	N/A	$14.09 -1.6%	N/A	+134.9%	$189.13M	N/A	N/A	2,021	Gap Down
IFRX InflaRx	2.7047 of 5 stars	$2.74 +5.0%	$7.00 +155.5%	+167.9%	$188.69M	$29.33K	N/A	60	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XLO) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xilio Therapeutics (XLO) Competitors

XLO vs. IMDX, ARTV, JMAC, IFRX, and TLSA

How does Xilio Therapeutics compare to Oncocyte?

Summary

How does Xilio Therapeutics compare to Artiva Biotherapeutics?

Summary

How does Xilio Therapeutics compare to Maxpro Capital Acquisition?

Summary

How does Xilio Therapeutics compare to InflaRx?

Summary

How does Xilio Therapeutics compare to Tiziana Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xilio Therapeutics (XLO) Competitors

XLO vs. IMDX, ARTV, JMAC, IFRX, and TLSA

How does Xilio Therapeutics compare to Oncocyte?

Do analysts rate IMDX or XLO?

Which has more risk and volatility, IMDX or XLO?

Does the media favor IMDX or XLO?

Do insiders and institutionals believe in IMDX or XLO?

Which has preferable valuation & earnings, IMDX or XLO?

Is IMDX or XLO more profitable?

Summary

How does Xilio Therapeutics compare to Artiva Biotherapeutics?

Is ARTV or XLO more profitable?

Which has more volatility & risk, ARTV or XLO?

Which has better earnings & valuation, ARTV or XLO?

Do analysts recommend ARTV or XLO?

Do institutionals and insiders believe in ARTV or XLO?

Does the media refer more to ARTV or XLO?

Summary

How does Xilio Therapeutics compare to Maxpro Capital Acquisition?

Is XLO or JMAC more profitable?

Which has more volatility & risk, XLO or JMAC?

Do analysts prefer XLO or JMAC?

Do insiders & institutionals hold more shares of XLO or JMAC?

Which has stronger earnings and valuation, XLO or JMAC?

Does the media prefer XLO or JMAC?

Summary

How does Xilio Therapeutics compare to InflaRx?

Do insiders and institutionals believe in IFRX or XLO?

Does the media refer more to IFRX or XLO?

Which has more volatility & risk, IFRX or XLO?

Is IFRX or XLO more profitable?

Do analysts recommend IFRX or XLO?

Which has stronger valuation and earnings, IFRX or XLO?

Summary

How does Xilio Therapeutics compare to Tiziana Life Sciences?

Which has preferable earnings & valuation, XLO or TLSA?

Is XLO or TLSA more profitable?

Do analysts rate XLO or TLSA?

Which has more risk and volatility, XLO or TLSA?

Do institutionals and insiders have more ownership in XLO or TLSA?

Does the media prefer XLO or TLSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools